USA-based holding company PDL BioPharma (Nasdaq: PDLI) has appointed Dominique Monnet to the position of president.
Mr Monnet has 30 years of experience in the drug industry, most recently as chief marketing officer of US firm Alexion Pharmaceuticals (Nasdaq: ALXN) in 2014-2015, where he was responsible for commercial operations in the USA and Latin America, and oversaw new products and global business operations functions.
"PDL has put itself in an excellent financial position to capitalize on these opportunities"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze